JP2024518555A5 - - Google Patents
Info
- Publication number
- JP2024518555A5 JP2024518555A5 JP2023570166A JP2023570166A JP2024518555A5 JP 2024518555 A5 JP2024518555 A5 JP 2024518555A5 JP 2023570166 A JP2023570166 A JP 2023570166A JP 2023570166 A JP2023570166 A JP 2023570166A JP 2024518555 A5 JP2024518555 A5 JP 2024518555A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- formula
- acceptable salt
- propionylpyridine
- cyclopropanecarboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US63/188,498 | 2021-05-14 | ||
| US202263318508P | 2022-03-10 | 2022-03-10 | |
| US63/318,508 | 2022-03-10 | ||
| PCT/US2022/029117 WO2022241174A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024518555A JP2024518555A (ja) | 2024-05-01 |
| JP2024518555A5 true JP2024518555A5 (cg-RX-API-DMAC7.html) | 2025-05-21 |
| JP7818623B2 JP7818623B2 (ja) | 2026-02-20 |
Family
ID=81927791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570166A Active JP7818623B2 (ja) | 2021-05-14 | 2022-05-13 | 置換ヘテロ環化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11884650B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4337648B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7818623B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240008338A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022272725A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023023726A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218579A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3059456T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308422A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013351A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202311248A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022241174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| EP4337650A1 (en) * | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) * | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922841B8 (en) * | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| US20230295119A1 (en) | 2020-04-14 | 2023-09-21 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| EP4337650A1 (en) | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| US20240317718A1 (en) | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
-
2022
- 2022-05-13 KR KR1020237042732A patent/KR20240008338A/ko active Pending
- 2022-05-13 CA CA3218579A patent/CA3218579A1/en active Pending
- 2022-05-13 TW TW111118147A patent/TW202311248A/zh unknown
- 2022-05-13 JP JP2023570166A patent/JP7818623B2/ja active Active
- 2022-05-13 US US17/743,615 patent/US11884650B2/en active Active
- 2022-05-13 BR BR112023023726A patent/BR112023023726A2/pt not_active Application Discontinuation
- 2022-05-13 MX MX2023013351A patent/MX2023013351A/es unknown
- 2022-05-13 IL IL308422A patent/IL308422A/en unknown
- 2022-05-13 ES ES22727681T patent/ES3059456T3/es active Active
- 2022-05-13 EP EP22727681.3A patent/EP4337648B1/en active Active
- 2022-05-13 WO PCT/US2022/029117 patent/WO2022241174A1/en not_active Ceased
- 2022-05-13 AU AU2022272725A patent/AU2022272725A1/en not_active Abandoned
-
2023
- 2023-12-14 US US18/539,519 patent/US20240124421A1/en active Pending